Format
Sort by

Send to:

Choose Destination

Results: 5

1.

Effects of dalcetrapib in patients with a recent acute coronary syndrome.

Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators.

N Engl J Med. 2012 Nov 29;367(22):2089-99. doi: 10.1056/NEJMoa1206797. Epub 2012 Nov 5.

2.

Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.

Schwartz GG, Olsson AG, Ballantyne CM, Barter PJ, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Shah PK, Tardif JC, Chaitman BR, Duttlinger-Maddux R, Mathieson J; dal-OUTCOMES Committees and Investigators.

Am Heart J. 2009 Dec;158(6):896-901.e3. doi: 10.1016/j.ahj.2009.09.017.

PMID:
19958854
3.

A distinctive type of widespread congenital melanocytic nevus with large nodules.

Rose C, Kaddu S, El-Sherif TF, Kerl H.

J Am Acad Dermatol. 2003 Oct;49(4):732-5.

PMID:
14512930
4.

Alterations of sodium channel kinetics and gene expression in the postinfarction remodeled myocardium.

Huang B, El-Sherif T, Gidh-Jain M, Qin D, El-Sherif N.

J Cardiovasc Electrophysiol. 2001 Feb;12(2):218-25.

PMID:
11232622
5.

Polyunsaturated fatty acids and cardiovascular events: a fish tale.

Bigger JT Jr, El-Sherif T.

Circulation. 2001 Feb 6;103(5):623-5. No abstract available.

Format
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk